Rudolf Kotula, MD
Infectious Disease · Omaha, NENPI 1063477834
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $184,020 of the $221,095 with a category attached, or 83.2%. 33 manufacturers reported payments, led by GSK at 56.7% of the total. 2025 is the largest year on record at $53,690, more than ten times the $2,809 reported in 2019. Among infectious disease clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 646 payments — averaging $342.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$125K
- Gilead$84K
- Viiv Healthcare Company$2K
- Pfizer$2K
- AbbVie$1K
- Merck$1K
- plus $5K from 27 others
Across 21 payments — averaging $14,256 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$207K
- Gilead$66K
- Eli Lilly$26K
What the payments were for
- Consulting fees$1,4001%
- Speaking & faculty fees$184,02083%
- Travel & lodging$19,9249%
- Food & beverage$15,2127%
- Education$5390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 106 | $125,387 |
| Gilead | 163 | $84,393 |
| Viiv Healthcare Company | 61 | $2,194 |
| Pfizer | 18 | $1,712 |
| AbbVie(2 entities) | 67 | $1,208 |
| Merck | 46 | $1,007 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $587 |
| Melinta Therapeutics, LLC | 24 | $524 |
| Astellas Pharma US Inc | 12 | $422 |
| Insmed, Inc. | 17 | $369 |
| Aimmune Therapeutics, Inc. | 7 | $342 |
| Ferring Pharmaceuticals Inc. | 14 | $326 |
| Amgen(2 entities) | 8 | $315 |
| Johnson & Johnson(2 entities) | 16 | $306 |
| Grifols USA, LLC | 10 | $251 |
| Shionogi Inc | 7 | $242 |
| Paratek Pharmaceuticals, Inc. | 12 | $238 |
| CSL Behring | 6 | $226 |
| Janssen Products, LP | 2 | $170 |
| Genentech, Inc. | 1 | $134 |
| Hospira, Inc. | 7 | $116 |
| Octapharma USA, Inc. | 3 | $97 |
| Tactile Systems Technology Inc | 1 | $78 |
| Angiodynamics, Inc. | 1 | $70 |
| Janssen Scientific Affairs, LLC | 1 | $67 |
| Bio Products Laboratory USA, Inc. | 3 | $66 |
| Sanofi Pasteur Inc. | 3 | $55 |
| Pharming Healthcare, Inc. | 2 | $43 |
| Smith+Nephew | 3 | $42 |
| Dynavax Technologies Corporation | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Shire North American Group Inc | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$221,095 in reported general payments places this provider in the 95th percentile of 55 infectious disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DovatoDolutegravir Sodium/Lamivudine | 24 | $76,093 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 26 | $54,080 |
| ErtapenemErtapenem Sodium | 28 | $12,234 |
| Methenamine Hippurate | 204 | $7,323 |
| Vancomycin Hcl | 22 | $2,761 |
| CeftriaxoneCeftriaxone Sodium | 45 | $2,319 |
| Estradiol | 12 | $1,138 |
| Moxifloxacin Hcl | 13 | $891 |
| Cefadroxil | 19 | $591 |
| Cefazolin Sodium | 16 | $531 |
| Fluconazole | 16 | $513 |
| Cefdinir | 26 | $506 |
| NitrofurantoinNitrofurantoin Macrocrystal | 15 | $487 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $303 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 32 | $242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato | $2,194 | $76,09324 claims |
| Grifols USA, LLCGamunex-C | $251 | $54,08026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 55 infectious disease providers in Nebraska.
Other infectious disease in Omaha
- Marvin BittnerOmaha$100K
- Mark RuppOmaha$76K
- Trevor VanschooneveldOmaha$56K
- Nada FadulOmaha$26K
- Alison FreifeldOmaha$15K
- Amir GholamiOmaha$12K
- Andre KalilOmaha$11K
- Kelly CawcuttOmaha$11K
- Diana FlorescuOmaha$11K
- Jeffrey SartinOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.